Wisconsin Confirms Five Mpox Cases as US Total Climbs to 535

The Wisconsin Department of Health Services on Tuesday confirmed five mpox cases across the state’s northern and southeastern regions, the first locally identified infections of 2026 and a small slice of a national tally that reached 535 confirmed cases by May 3, according to figures the department cited from the U.S. Centers for Disease Control and Prevention. The agency called the public risk low while urging residents in higher-exposure groups to talk with a clinician about vaccination.

The bigger picture sits a layer underneath. Mpox case counts have crept upward in several U.S. metros since March, a quiet trend that has run under the public’s post-2022 assumption that the outbreak was finished. The Wisconsin cluster is one of the first heartland signals that the floor has lifted.

Where the Five Wisconsin Cases Surfaced

State health officials described the five cases as concentrated in northern and southeastern Wisconsin, without naming specific counties or municipalities. All five were confirmed between January and May 26, 2026. The department has not released patient demographics, hospitalization status, or exposure sources.

What the numbers actually look like in context:

• 5 confirmed Wisconsin mpox cases year to date, all reported between January 1 and May 26, 2026
• 2 regions of the state involved, northern and southeastern
• 0 Wisconsin mpox cases reported during the same January-to-May window in 2025
• 535 U.S. confirmed cases as of May 3, the most recent national number the state agency cited

The state’s framing matters. DHS labelled the risk to Wisconsinites as low, a phrase that carries a specific meaning in public-health communication: most residents do not need to change behavior, but a defined slice of the population should. That slice is what the rest of the guidance is about.

The National Backdrop Behind the Wisconsin Cluster

Wisconsin’s report lands in the middle of a slow national rise. The CDC’s monthly U.S. case data dashboard shows the majority of 2026 infections remain clade II, the variant tied to the 2022 outbreak, with most patients either unvaccinated or having completed only the first of two recommended JYNNEOS doses.

New York City has carried a disproportionate share of the early-2026 activity. Comparing the visible jurisdictions:

NYC alone logged 398 cases in 2025 and 45 between January 1 and March 10 of this year, according to the city’s municipal mpox dashboard. The pace then quickened. Public-health surveillance teams are watching whether the spring uptick continues into summer travel season.

Clade I, the Variant Health Officials Are Tracking

Two clades of monkeypox virus (mpox) circulate. Clade II is the milder, more transmissible lineage that drove the 2022 global outbreak and accounts for nearly every U.S. case since then. Clade I is the more virulent lineage that has been spreading in Central and Eastern Africa and that, until 2024, had never been detected in the United States.

How Many Clade I Cases the U.S. Has Logged

From November 2024 to February 2026, the CDC counted 11 confirmed clade I cases on U.S. soil, almost all of them travel-associated and almost all subclade Ib, per the agency’s clade I outbreak tracking page. Three of those involved patients with no recent international travel, an early signal of limited domestic transmission. The 2026 count has continued to add cases in Missouri, Connecticut, and New York City.

Why the Variant Distinction Matters for Wisconsin

Wisconsin’s five cases have not been publicly identified as clade I. The state’s release pattern, and the broader national distribution, suggests they are clade II. That matters because the vaccination guidance, the symptoms, and the contact-tracing protocols are largely the same for both, but clinicians treat the clade I confirmation as a trigger for stricter isolation and broader contact outreach. State-level genotyping is what closes that loop.

Who Health Officials Recommend Talk to a Provider About JYNNEOS

The Wisconsin Department of Health Services pointed residents in three categories toward a clinician conversation about vaccination. The categories track the CDC’s national JYNNEOS clinical considerations and have not materially shifted since 2024.

• Gay or bisexual men, and men who have sex with men, including people who were assigned female at birth, who have had more than one sexual partner in the last six months
• Travelers who may have sexual exposure with a partner in a region where mpox transmission is active, particularly parts of Central and Eastern Africa and Western Europe where clade I has surfaced
• Close contacts of a confirmed mpox case, including healthcare workers whose duties create plausible exposure risk

JYNNEOS (the Modified Vaccinia Ankara vaccine sold under the Bavarian Nordic brand) is a two-dose series. The second shot is given four weeks after the first; if the gap stretches longer, the CDC’s instruction is to complete the second dose rather than restart. Vaccine effectiveness studies published by federal researchers estimate post-vaccination breakthrough infection in under 1% of fully vaccinated people.

The honest gap in the U.S. response is the gulf between people eligible for JYNNEOS and people who have completed both doses. Federal data from earlier coverage windows showed first-dose uptake outrunning second-dose completion in nearly every priority population. That gap is the part of the system most likely to convert a small cluster into a sustained one.

Symptoms, Timing, and the Mpox Rash Pattern

The clinical picture is consistent enough that most clinicians can identify it without a laboratory test, though laboratory confirmation is what counts for the state’s case count. Wisconsin DHS described the symptom sequence as follows:

1. Day 0 to 3: A new, unexplained rash appears. It develops into hard, round, fluid-filled blisters that look distinct from common chickenpox or shingles lesions.
2. Concurrent or just before: Some patients report fever, chills, muscle aches, or swollen lymph nodes. The fever often precedes the rash by one to three days, though the order can flip and the rash can come first.
3. Two to four weeks: Lesions typically scab and resolve. The patient stays contagious until all lesions have crusted, fallen off, and a fresh skin layer has formed underneath.

The transmission routes the agency named are intimate face-to-face contact (extended close talking or breathing), sustained skin-to-skin contact, and contact with linens, towels, or other items contaminated by an infected person’s fluids or sores. Casual passing contact in a shared public space is not the threat profile.

Prevention Steps Residents Can Take This Week

The state’s prevention list is short and concrete. None of it is novel, and all of it is more useful when applied before symptoms appear in a partner or contact.

• Learn the symptom pattern, especially the rash sequence, so a new lesion gets evaluated rather than dismissed
• Watch your own body and your partners’ bodies for new rashes or skin lesions before sexual contact
• Have direct conversations with sexual partners about mpox, other sexually transmitted infections, and HIV status
• If you fall in one of the higher-risk groups, complete both JYNNEOS doses on schedule rather than stopping after the first
• If you develop a suspicious rash, contact a clinician and isolate from household members and sexual partners until a diagnosis is reached

Wisconsin’s count stands at five. Whether it stays in single digits through the summer is the next data point that matters, and the answer will be visible in the department’s monthly updates rather than in any single press release.

Frequently Asked Questions

How many mpox cases has Wisconsin confirmed in 2026?

Five, as of May 26, 2026. The Wisconsin Department of Health Services described them as spread across the state’s northern and southeastern regions and did not name specific counties or release patient demographics.

Is the mpox vaccine free in Wisconsin?

JYNNEOS is available without out-of-pocket cost through most public-health channels and many private clinicians for people who meet federal eligibility criteria. Coverage details vary by insurance status, so the state’s recommendation is to call your clinic or the local public-health department before booking.

What is the difference between clade I and clade II mpox?

Clade II is the lineage that drove the 2022 global outbreak and accounts for nearly all U.S. cases since. Clade I is the more virulent African lineage that began appearing in the U.S. through travel-associated cases starting in November 2024. Wisconsin’s five confirmed cases have not been publicly identified as clade I.

How is mpox spread?

Mpox spreads through intimate face-to-face contact (extended close talking or breathing), sustained skin-to-skin contact, and contact with linens, towels, or items contaminated with an infected person’s fluids or sores. Brief passing contact in a shared public space is not the typical transmission route.

How long does mpox last?

The typical course runs two to four weeks from rash onset. Patients are considered contagious until all lesions have scabbed, fallen off, and been replaced by a fresh layer of skin underneath.

How effective is the JYNNEOS vaccine?

Federal effectiveness studies estimate that post-vaccination breakthrough mpox infection occurs in under 1% of fully vaccinated people. The vaccine requires two doses given four weeks apart, and the CDC instruction is to complete the second dose even if the four-week window has passed.

Where can Wisconsin residents report symptoms or seek testing?

Residents should contact their primary care clinician, a local sexual-health clinic, or their county or tribal health department. Testing is conducted through commercial and public-health laboratories, and a positive result is reported to the state by the testing facility.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Mpox is a notifiable infectious disease; readers with possible exposure, suggestive symptoms, or questions about JYNNEOS vaccination should consult a qualified healthcare provider or contact their state or local public-health department. Case counts and guidance are accurate as of publication on May 28, 2026, and may change as new surveillance data is released.